Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.

MLA

Romano, Alessandra, et al. “Salvage Therapy with Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Patients.” European Journal of Haematology, vol. 93, no. 3, Sept. 2014, pp. 207–13. EBSCOhost, https://doi.org/10.1111/ejh.12325.

APA

Romano, A., Chiarenza, A., Conticello, C., Cavalli, M., Vetro, C., Di Raimondo, C., Cunsolo, R., Palumbo, G. A., & Di Raimondo, F. (2014). Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. European Journal of Haematology, 93(3), 207–213. https://doi.org/10.1111/ejh.12325

Chicago

Romano, Alessandra, Annalisa Chiarenza, Concetta Conticello, Maide Cavalli, Calogero Vetro, Cosimo Di Raimondo, Rosario Cunsolo, Giuseppe Alberto Palumbo, and Francesco Di Raimondo. 2014. “Salvage Therapy with Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Patients.” European Journal of Haematology 93 (3): 207–13. doi:10.1111/ejh.12325.